Akebia Therapeutics, Inc.NASDAQ: AKBA

Akebia Therapeutics Announces Participation in Upcoming Investor Conferences

· Issued by Akebia Therapeutics, Inc. via PR Newswire

CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following investor conferences:

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

Piper Sandler 33rd Annual Virtual Healthcare ConferenceNovember 29 – December 2, 2021 John Butler will participate in a virtual fireside chat, which will be available on the conference site prior to the virtual event. 

4th Annual Evercore ISI HealthCONx Conference November 30 - December 2, 2021John Butler will participate in a virtual fireside chat, which will be presented on Tuesday, November 30 at 4:45 on the conference site.

Where applicable, webcasts of Akebia's fireside chats will be made available on the Investors section of the Company's website at https://ir.akebia.com.

About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics ContactMercedes CarrascoMcarrasco@akebia.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-participation-in-upcoming-investor-conferences-301431123.html

SOURCE Akebia Therapeutics

View original source (PR Newswire)